Twist Bioscience Co. (NASDAQ:TWST) Shares Bought by Van ECK Associates Corp

Van ECK Associates Corp boosted its stake in shares of Twist Bioscience Co. (NASDAQ:TWST) by 56.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 740 shares of the company’s stock after acquiring an additional 267 shares during the period. Van ECK Associates Corp’s holdings in Twist Bioscience were worth $34,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in TWST. Thrivent Financial for Lutherans acquired a new position in Twist Bioscience during the third quarter worth $43,992,000. State Street Corp grew its holdings in shares of Twist Bioscience by 19.9% during the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after buying an additional 526,028 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Twist Bioscience by 188.5% during the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after buying an additional 521,272 shares in the last quarter. Jennison Associates LLC grew its holdings in shares of Twist Bioscience by 80.2% during the fourth quarter. Jennison Associates LLC now owns 680,778 shares of the company’s stock worth $31,636,000 after buying an additional 302,884 shares in the last quarter. Finally, Fred Alger Management LLC grew its holdings in shares of Twist Bioscience by 17.1% during the third quarter. Fred Alger Management LLC now owns 767,149 shares of the company’s stock worth $34,660,000 after buying an additional 112,272 shares in the last quarter.

Twist Bioscience Price Performance

Shares of TWST opened at $41.20 on Tuesday. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The stock has a market cap of $2.46 billion, a PE ratio of -12.19 and a beta of 1.87. The firm has a 50-day simple moving average of $47.95 and a two-hundred day simple moving average of $45.73. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. During the same period last year, the business earned ($0.75) earnings per share. The business’s revenue for the quarter was up 24.1% on a year-over-year basis. As a group, analysts forecast that Twist Bioscience Co. will post -2.12 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Barclays set a $58.00 target price on shares of Twist Bioscience and gave the stock an “overweight” rating in a report on Monday, February 3rd. Wolfe Research assumed coverage on shares of Twist Bioscience in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price for the company. TD Cowen reaffirmed a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a report on Tuesday, November 26th. Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Finally, Robert W. Baird raised their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and an average price target of $54.40.

Insider Buying and Selling at Twist Bioscience

In related news, CEO Emily M. Leproust sold 5,200 shares of Twist Bioscience stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total value of $256,620.00. Following the completion of the transaction, the chief executive officer now owns 667,318 shares in the company, valued at approximately $32,932,143.30. The trade was a 0.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Adam Laponis sold 5,886 shares of Twist Bioscience stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $43.26, for a total transaction of $254,628.36. Following the completion of the transaction, the chief financial officer now owns 110,096 shares of the company’s stock, valued at $4,762,752.96. This trade represents a 5.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 37,180 shares of company stock worth $1,821,971 over the last three months. Insiders own 3.01% of the company’s stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.